University of Groningen

Synthesis and Enantiomeric Separation of a Novel Spiroketal Derivative

Fuggetta, Maria Pia; De Mico, Antonella; Cottarelli, Andrea; Morelli, Franco; Zonfrillo, Manuela; Ulgheri, Fausta; Peluso, Paola; Mannu, Alberto; Deligia, Francesco; Marchetti, Mauro

Published in:
Journal of Medicinal Chemistry

DOI:
[10.1021/acs.jmedchem.6b01046](https://doi.org/10.1021/acs.jmedchem.6b01046)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Fuggetta, M. P., De Mico, A., Cottarelli, A., Morelli, F., Zonfrillo, M., Ulgheri, F., Peluso, P., Mannu, A., Deligia, F., Marchetti, M., Roviello, G., Reyes Romero, A., Dömling, A., & Spanu, P. (2016). Synthesis and Enantiomeric Separation of a Novel Spiroketal Derivative: A Potent Human Telomerase Inhibitor with High in Vitro Anticancer Activity. *Journal of Medicinal Chemistry*, 59(19), 9140-9149.
<https://doi.org/10.1021/acs.jmedchem.6b01046>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Synthesis and Enantiomeric Separation of a Novel Spiroketal Derivative: A Potent Human Telomerase Inhibitor with High in Vitro Anticancer Activity

Maria Pia Fuggetta,^{*,†} Antonella De Mico,[‡] Andrea Cottarelli,[†] Franco Morelli,[§] Manuela Zonfrillo,[†] Fausta Ulgheri,^{||} Paola Peluso,^{||} Alberto Mannu,^{||} Francesco Deligia,^{||} Mauro Marchetti,^{||} Giovanni Roviello,[⊥] Atilio Reyes Romero,[#] Alexander Dömling,[#] and Pietro Spanu^{*,||}

[†]Istituto di Farmacologia Traslazionale, Consiglio Nazionale delle Ricerche, Via Fosso del Cavaliere, 00133 Roma, Italy

[‡]Istituto di Biologia e Patologia Molecolare, Consiglio Nazionale delle Ricerche, Piazzale Aldo Moro 5, 00185 Roma, Italy

[§]Istituto di Genetica e Biofisica, Consiglio Nazionale delle Ricerche, Via Pietro Castellino 111, 80131 Napoli, Italy

^{||}Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Trav. La Crucca 3, 07100 Sassari, Italy

[⊥]Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Via Mezzocannone 16, 80134 Naples, Italy

[#]Department of Drug Design, School of Pharmacy, University of Groningen, Antonius Deusinglaan 1 Postbus 196, 9700 AD, Groningen, The Netherlands

S Supporting Information

ABSTRACT: The synthesis, the enantiomeric separation, and the characterization of new simple spiroketal derivatives have been performed. The synthesized compounds have shown a very high anticancer activity. Cell proliferation assay showed that they induce a remarkable inhibition of cell proliferation in all cell lines treated, depending on culture time and concentration. The compounds have also shown a potent nanomolar human telomerase inhibition activity and apoptosis induction. CD melting experiments demonstrate that spiroketal does not affect the G-quadruplex (G4) thermal stability. Docking studies showed that telomerase inhibition could be determined by a spiroketal interaction with the telomerase enzyme.

INTRODUCTION

Numerous complex natural products containing spiroketals framework have been isolated over the years from marine or terrestrial sources and have shown a wide range of important biological activities.^{1,2} Among them, the spongistatins **1** are a family of marine macrolides that display remarkable antitumor activity,³ integrator **2** is an HIV-1 integrase inhibitor,⁴ reveromycins **3** are polyketide type antibiotics inhibitors of mitogenic epidermal growth factor (EGF) activity,^{5–7} tautomycin **4** and okadaic acid **5** are protein phosphatase inhibitors,^{8–10} spirofungin **6** selectively inhibits the activity of isoleucyl-tRNA synthetase and displays antiproliferative activity of cancer cells,¹¹ and the rubromycins exhibit an array of antimicrobial activity, cytotoxicity, and potent ability to inhibit human telomerase (Figure 1).^{12–16} Many groups started to investigate the possibility of reducing the complexity of spiroketal natural products while preserving their biological activity by focusing on the role of the spiroketal core on the biological activity of their natural models.^{17–19}

The essential role of rubromycins spiroketal subunit for telomerase inhibition was demonstrated,¹² and natural inspired spiroketals **8**, **9**, and **10** were synthesized showing interesting

biological activity often retained from their parent natural products, while more recently, the simple spiroketal metabolite dinemasone **A 11** was isolated from the fungus *Dinemasporium strigosum* and showed antimicrobial activity (Figure 2).^{20–23} These results clearly demonstrate that simple spiroketals inspired to natural bioactive products can be privileged scaffolds for new lead compounds endowed with interesting biological activity.

Recently, some of us have synthesized a new structurally simplified spiroketal **12** that has shown potent antitumor activity against tumor cells of various nature and histotype (Figure 3).²⁴ The simple spiroketal structure of this compound is equipped with different stereocenters, and its synthesis afforded a stereoisomeric mixture of the spiroketal **12** that was initially submitted to biological assay. Intrigued by the potent antitumor activity of the stereoisomeric mixture, we decided to investigate the activity of the enantiomerically pure spiroketals. Here we describe the synthesis and the characterization of the stereoisomeric mixture of the spiroketal **12**, their

Received: July 14, 2016

Published: September 3, 2016

Figure 1. Biologically active naturally occurring spiroketals.

Figure 2. Biologically active simple spiroketals.

Figure 3. Structure of the new biologically active simple spiroketal.

stereoisomeric separation, and the biological evaluation of the stereoisomeric mixture and the enantiomerically pure spiroketals. On the basis of docking and circular dichroism (CD) studies, we highlighted that spiroketals induced telomerase inhibition could be determined by a spiroketal interaction with the telomerase enzyme rather than by a G-quadruplex (G4) stabilization mechanism.

RESULTS AND DISCUSSION

Chemistry. The synthesis of the spiroketal derivative **12** has been performed via an oxidation rearrangement of 2-furyl ketone **15** readily available by reaction of furyllithium with δ -

hexalactone **14** as shown in Scheme 1.^{25,26} Starting from the racemic δ -hexalactone **14**, only two spiroketal diastereomers in 3:1 isomers ratio were detected via NMR, each consisting of a racemic mixture. The stereoisomers detected in the reaction mixture were supposed to have the configurations shown in Scheme 1 for compounds **12a,b** [(2*S*,6*S*,8*R*) and (2*R*,6*R*,8*S*)] and **12c,d** [(2*R*,6*S*,8*R*) and (2*S*,6*R*,8*S*)] because they are the only stereoisomers favored from two anomeric effects derived from the axial–axial arrangement of the spiro C–O bonds.^{25–27}

The configuration of the major diastereomers **12a,b** was supported by the observation of a nuclear Overhauser enhancement between the C-2 hydrogen and the C-8 hydrogen. As previously reported on similar spiroketals, the minor diastereomers **12c,d** were assigned as the thermodynamically less stable corresponding C-2 epimers of **12a,b**. On the basis of the positive results of the biological tests performed on the mixture of stereoisomers **12a–d** (see below), the separation of the single stereoisomers was then performed by using chiral HPLC in order to test their individual biological activity. Finally in order to confirm the absolute configuration of the recovered stereoisomers, we carried out the synthesis of the spiroketal mixture of **12a** and **12c** starting from the enantiopure (*R*)- δ -hexalactone **14** (Scheme 1).

Chiral HPLC of the Stereoisomers Mixture of 12a–d.

With the aim to have at disposal milligram amounts of pure enantiomers for biological tests, the enantioseparability of the mixture containing the stereoisomers **12a–d** was investigated on two polysaccharide-based chiral columns (Chiralcel OD-H and Chiralpak IA) by using hex/IPA 95:5 as mobile phase

Scheme 1. Synthesis of spiroketal stereoisomers starting from racemic and enantiopure (*R*)- δ -hexalactone 14

(MP) at flow rate FR = 0.8 mL/min. Four separated peaks were observed on both columns (Table 1). In general, the best

Table 1. HPLC of Stereoisomeric Mixture of 12a–d by Using hex/IPA 95:5 as Mobile Phase at FR = 0.8 mL/min

compd	chiral column							
	Chiralcel OD-H				Chiralpak IA			
	<i>t</i> [min]	<i>k</i>	α	R_s	<i>t</i> [min]	<i>k</i>	α	R_s
16	9.16	1.54	1.08	0.7	8.25	1.17	1.23	1.7
	9.58	1.66			9.31	1.44		
12a	11.24	2.12	1.13	1.2	15.94	3.19	1.51	5.7
12b	12.23	2.40			22.01	4.81		

column/MP chromatographic system can be selected as a suitable compromise between a high enough enantioselectivity value, a baseline resolution ($R_s \geq 1.5$), and a run-time as short as possible to complete the analysis. On this basis, Chiralcel OD-H was chosen for the multimilligram recovery of the stereoisomers. Indeed, although baseline resolution was only achieved on Chiralpak IA (Figure 4), shorter elution times were obtained on Chiralcel OD-H, allowing recovery of the enantiomers 12a and 12b within 15 min.

Each peak recovered by using Chiralcel OD-H was characterized by NMR spectroscopy. The NMR spectra of compounds eluted at 9.16 and 9.58 min (Table 1) allowed the

identification of compound 16 probably derived by on-column rearrangement of 12, whereas it was possible to assign the signals of compounds eluting at 11.24 and 12.23 min to the couple 12a (2*S*,6*S*,8*R*) and 12b (2*R*,6*R*,8*S*) (Figure 5).

However, 12 showed low on-column stability, and this fact limited the recovery yield. Indeed, the injection of 28.0 mg of isomeric mixture on Chiralcel OD-H produced 3.9 mg of 12a and 3.3 mg of 12b (>99% ee, 26% yield), whereas 45.6 mg of isomeric mixture produced 5.6 mg of each enantiomer, namely, 12a and 12b (>99% ee, 25% yield) on Chiralpak IA. To increase throughput, the technique of boxcar injections was used for all recoveries. The minor diastereoisomeric couple 12c,d was not detected by HPLC analysis probably because of the low on-column stability of the spiroketal 12. The enantiomer elution order was determined by injection of a sample of diastereomeric mixture 12a,c obtained from the enantiopure (*R*)- δ -hexalactone 14 (Scheme 1).

Biology. Antiproliferative Activity of Spiroketal Stereoisomeric Mixture 12a–d. First, biological studies on the stereoisomeric mixture of 12a–d have been carried out using representative human tumor cell lines with different histological origin: MCF-7 breast carcinoma, M14 melanoma, H125 pulmonary carcinoma, HT-29 colon carcinoma, HL-60 promyelocytic leukemia, and SH-SY5Y neuroblastoma. The tumor cell growth has been evaluated by counting viable cells number by a trypan blue dye exclusion test. The results, illustrated in Figure 6 in terms of viable cell number, showed

Figure 4. HPLC separation on Chiralpak IA.

Figure 5. NMR structural characterization of compounds recovered by means of chiral HPLC on Chiralcel OD-H.

that spiroketal stereoisomeric mixture **12a–d** used at different concentrations (7.8 nM, 15.6 nM, 31.2 nM, 62.5 nM, 125 nM, 250 nM) for culture times from 24 to 72 h induced a remarkable inhibition of cell proliferation. The cell growth inhibition was observed in all treated tumor cells and is time and dose correlated. In particular, the treatment with 250 nM of stereoisomeric mixture (**12a–d**) induced a potent cytotoxic effect in all lines, since more than 90% of treated tumor cells were found to be dead as early as 24 h after treatment.

Antiproliferative Activity of Enantiomerically Pure Enantiomers **12a and **12b**.** The evaluation of antiproliferative effects has been also carried out using the enantiomerically pure enantiomers **12a** (2*S*,6*S*,8*R*) and **12b** (2*R*,6*R*,8*S*) obtained via chiral HPLC separation. The tumor cell line M14 (human melanoma) has been used as representative tumor cell line to compare the antiproliferative effectiveness of **12a** and **12b** with respect to the stereoisomeric mixture **12a–d**. Treatment was performed with serial concentrations of **12a**, **12b**, and the racemic mixture of stereoisomers **12a–d** as reference compound from 62.5 nM to 250 nM (12.5, 25, 50, μ g/mL) at culture times varying from 24 to 72 h. The effect of **12a**, **12b**, and **12a–d** on cell proliferation of melanoma cell line M14 was determined by cell counts in trypan blue (dye exclusion test) using a hemocytometer (see below). Cell proliferation results show that treatment with enantiopure **12a**, **12b**, and **12a–d**

Figure 6. Antiproliferative effect of the stereoisomeric mixture of **12a–d** on human tumor cell lines: M14 melanoma, H125 pulmonary carcinoma, HL-60 promyelocytic leukemia, HT-29 colon carcinoma, MCF-7 breast carcinoma, and SH-SY5Y neuroblastoma cell line. Cell growth kinetics was evaluated in terms of number of viable cells. The cell proliferation, viability, and death have been determined by means of cell counts in trypan blue (dye exclusion test). Data are expressed in terms of number of viable cells. Measurements were done in triplicate, and bars represent $\pm$ SE of the mean of three wells. Values are referred to a representative experiment, from least three independent experiments.

stereoisomeric mixture at different concentrations always induces in the M14 cell line a remarkable inhibition of cell proliferation, depending on culture time and concentration (Figure 7). In addition, as shown in Figure 8, taking a reference

Figure 7. Effect of pure enantiomers **12a** and **12b** and stereoisomeric mixture **12a-d** on tumor cell growth of M14 melanoma cell line. Cells were cultured in complete medium containing the indicated concentrations of **12a**, **12b**, and **12a-d** for 6, 24, 48, and 72 h. Control groups were treated with DMSO alone. Cell proliferation was determined by trypan blue dye exclusion assay. Data are expressed in terms of viable cells number. Measurements were done in triplicate. Values of a representative experiment, from at least three independent experiments, represent the mean $\pm$ SE of three wells.

dose of 250 nM, the tumor growth inhibition is comparable for both enantiomers and the stereoisomeric mixture in M14 line by using a CellTiter 96 nonradioactive cell proliferation assay. The results are referenced to optical density (OD). Taken together, the results show a comparable effect of enantiomers **12a** and **12b** and the stereoisomeric mixture **12a-d** in inhibiting M14 cell growth. The inhibition activity of both enantiomers and the stereoisomeric mixture on M14 cell growth

is also substantially comparable when evaluated in terms of kinetic cell growth.

Proapoptotic in Vitro Activity. The role of apoptosis in the origin of the inhibitory effect of **12a-d** on cell proliferation has been previously investigated by flow cytometry.²⁴ In order to confirm this proapoptotic effect of **12a-d**, the activation of caspases 3/7, which are mediators of apoptosis, was analyzed upon exposure of SHSYSY neuroblastoma cell line to the **12a-d** mixture. In order to avoid an excessive cytotoxicity the experiments were performed using very low doses (7.8 nM, 15.6 nM, 31.2 nM) of the **12a-d** mixture and for a relative short time, 24 h. The levels of caspase activation in SHSYSY neuroblastoma cells were compared with untreated control cells arbitrarily set to 1.0. The results, expressed as caspase 3/7 activity fold increase, showed that the **12a-d** significantly increase caspase 3/7 activation at different concentrations. At 31.2 nM, the caspase 3/7 activity reached a maximum 8.2-fold increase at 24 h (Figure 9).

Telomerase in Vitro Activity. In order to provide additional information on the antitumor effects of **12a-d** on malignant cells, experiments were performed to test the in vitro influence of the compound on telomeric activity (TELMA), the enzyme strongly associated with cancer progression and cell immortalization.^{28–32} MCF-7, H-125 HT-29, and M14 tumor cells were exposed in vitro to 31.2–250 nM stereoisomeric mixture **12a-d**. After 48 h of treatment TELMA was evaluated. In all examined cell lines a reduction of TELMA was observed as shown in Table 2. The results were expressed as percentage of inhibition with respect to untreated cell line. The inhibition is concentration-dependent in all lines examined. In particular M14 melanoma cell line appears as the most sensible tumor line with respect to TELMA inhibition reaching around 62% of TELMA inhibition at the lower concentration of **12a-d** (31.2 nM). IC_{50} of **12a-d** ranged from 12.6 to 85.2 nM depending on the cell lines. To the best of our knowledge the spiroketal **12a-d** is one of the most potent telomerase inhibitor known.

Circular Dichroism Studies. Since a spiroketal telomerase inhibition effect could be a consequence from a stabilization of G4, CD spectroscopy was used to investigate the binding property of the spiroketal stereoisomeric mixture to telomeric G4.^{33,34} In order to investigate the influence of **12a-d** toward the G4 stability by a sequence taken from the human telomeric DNA, a 2.5 μ M solution of tel22 G4 has been incubated with 50 equiv of **12a-d** in two buffer systems: 0.01 M Tris-HCl (pH 7.5), 0.2 M KCl, and PBS 1 $\times$ (pH 7.5). The conformation adopted by tel22 G4, after annealing under the above-described experimental conditions, is essentially identical to that observed by Hudson et al.,³⁵ as confirmed by comparison of its CD spectrum with literature reports. Its stability has been analyzed by CD-melting experiments, monitoring the CD signal changes at 295 nm registered upon increasing the temperature in the range 10–90 $^{\circ}$ C (Figure 10). G4 exhibits a T_m of 69 $^{\circ}$ C in 0.01 M Tris-HCl (pH 7.5), 0.2 M KCl. In contrast, the G4 was markedly less stable in PBS 1 $\times$ (pH 7.5) exhibiting a T_m of 60 $^{\circ}$ C. After incubation with **12a-d**, CD-melting experiments (Figure 10) have been performed on the systems G4/12 in both the buffer systems, mixed in 1:50 ratio; these results show that **12a-d** do not affect the CD melting curve of the G4.

Molecular Modeling. No crystallographic data of human telomerase are available; however a homology model was elaborated based on the *Tribolium castaneum* structure in the past.³⁶ Skordalakes and co-workers highlighted further structural conservative elements between human and *Tribolium*

Figure 8. Effect of 250 nM of pure enantiomers **12a** and **12b** and stereoisomeric mixture **12a-d** on tumor cell growth of M14 melanoma cell line evaluated at 24, 48, and 72 h. Cell proliferation was determined by CellTiter 96 nonradioactive cell proliferation assay. Measurements of optical density (OD) were done in triplicate in three different experiments. Data are expressed in terms of percentage of cell growth inhibition with respect to control.

Figure 9. Apoptosis mediated by caspase 3/7 activation. Treatment of cells with various concentrations of **12a-d** for 24 h. The levels of caspase activation in SHSY5Y neuroblastoma cell line were compared with untreated control cells arbitrarily set to 1.0. Measurements were done in triplicate, and bars represent $\pm$ SE of the mean of three wells. Values are referred to a representative experiment, from at least three independent experiments.

Table 2. Dose-Dependent Percent of Inhibition of TELMA with Respect to Untreated Control Obtained by Stereoisomeric Mixture **12a-d**^a

tumor line	percent of inhibition of TELMA by 12a-d after 48 h			
	31.2 nM	62.5 nM	125 nM	250 nM
MCF7 breast cancer cell	0	37.5	67.9	78.6
M14 melanoma	62	63	74	82.6
H125 lung carcinoma	13.6	48.7	67.6	75.7
HT29 colon carcinoma	24	53.5	69	73.4

^aTELMA was detected by telomeric repeat amplification protocol enzyme-linked immunosorbent assay after 48 h. The percent of inhibition was calculated between the mean values of treated versus untreated control, and all experiments were done in triplicate.

castaneum telomerase. A conserved and solvent-exposed hydrophobic pocket to accommodate small molecules is formed by the thumb domains of α 20, α 21, α 22, and α 23 helices present in both species telomerases.³⁷ We were docking the different spiroketal stereoisomers into the presumed binding site formed by the four α -helices. We used Glide score to rank

Figure 10. Overlapped CD melting curves of tel22 (2.5 μ M, PBS 1 $\times$, pH 7.5) in the absence (green line) and presence of 50 equiv of **12a-d** (blue) and tel22 (2.5 μ M, 0.01 M Tris-HCl–0.2 M KCl, pH 7.5) in the absence (cyan line) and presence of 50 equiv of **12a-d** (red), recorded at 295 nm with a temperature increase of 1 $^{\circ}$ C/min;.

the poses of **12a-d** and Glide Emodel to fetch the best/worst ones. The ligand and the receptor site show nice shape and electrostatic complementarity. Our docking studies predicted several van der Waals interactions between the aliphatic moiety of the spiroketal scaffold and the hydrophobic residues Phe 482, Ile 556, Ile 550, Leu 554, and Phe 494 and hydrogen bonds between the hydroxyl, ether, and carbonyl oxygens and Leu 554, Asp 493, Asn 492, Arg 486, and Tyr 551. Next we used Scorpion analysis to rank ligand atoms individually in the context of cooperativity between a protein ligand complex to help in understanding the network interactions (Figure 11).³⁸

Scorpion analysis predicted **12a** and **12b** as the strongest binder. An exemplary Scorpion analysis of the highest scoring pose of **12a** is shown in Figure 11. The hydroxyl group makes a bifurcated hydrogen bonding with the amide carbonyls of Gly495 and Phe494. Plenty of hydrophobic contacts are formed between the double bond and the Arg557 and Leu554. The methyl group is buried deeply in the receptor pocket and shows a close contact to the m-carbon of Tyr551. The spiroketone carbonyl oxygen forms a dipolar interaction with the amide group of Gly553.

CONCLUSIONS

New structurally simplified spiroketals inspired to natural bioactive products have been synthesized. Their enantiomeric

Figure 11. Modeling of spiroketal **12a** into the *Tribolium castaneum* topoisomerase (PDB code 5CQG). Left: overview of the α -helical secondary structure around the binding pocket. Right: close-up view of the binding site with the spirooxindole **12a** shown as cyan sticks and the receptor residues as green sticks. van der Waals, hydrogen bonding, and dipolar interactions are shown in yellow, red, and cyan dotted lines, respectively. The binding distances are indicated in yellow. The picture was rendered with PyMol.

separation and characterization have been performed. The compounds have shown a high apoptosis induction and one of the most potent human telomerase inhibition activity known with also a very high anticancer activity. Cell proliferation results showed that the synthesized compounds always induce a remarkable inhibition of cell growth in all cell lines treated with spiroketals, depending on culture time and concentration. The inhibition activity of both enantiomers on cell grow is substantially comparable. These results confirm the previously proposed central role of spiroketals framework for telomerase inhibition activity. Furthermore, our CD melting experiments converge in showing that compounds **12a–d** do not affect the G4 thermal stability as revealed on tel22 human telomeric DNA. Our findings suggest that the ability of compounds **12a–d** to interfere with the telomerase activity is not due to any stabilization of telomeric G4 structures but follows other mechanisms. Docking studies showed several interactions between the spiroketal scaffold in the active site of telomerase and predict enantiomers **12a** and **12b** as the strongest binder of this enzyme.

■ EXPERIMENTAL SECTION

1. General Chemistry. All reactions were carried out under a nitrogen atmosphere. Solvents were distilled and dried by standard methods. NMR spectra were recorded at room temperature, unless stated otherwise, using a 400 MHz Varian Mercury spectrometer. Shifts have been recorded in ppm relative to CDCl_3 solvent residual peak. The following abbreviations have been used to explain the observed multiplicities: s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublets of doublets; t, triplet; td, triplet of doublets; m, multiplet; bs, broad singlet. All chemical reagents and solvents were purchased from commercial sources and used without further purification. Column chromatography was performed using 230–400 mesh silica gel. Thin-layer chromatography (TLC) was used to monitor progress of the reaction. The purity of the final compounds **12a–d** was determined by C, H, N analysis and was in agreement with the proposed structures with purity of $\geq 95\%$. The purity of final compounds **12a** and **12b** was determined by high performance liquid chromatography (HPLC) analysis, with the purity of compounds being higher than 95% and >99% of enantiomeric excess. HPLC instrument was a Agilent 1100 series HPLC system [high-pressure binary gradient system equipped with a diode-array detector operating at multiple wavelengths (220, 254, 280, 360 nm), a 20 μL sample loop, and a thermostated column compartment] using Chiralcel OD-H or Chiralpak IA operating as described in Chiral HPLC in the Experimental Section.

2-(Furan-2-yl)-6-methyltetrahydro-2H-pyran-2-ol (15). Butyllithium (16 mmol) and TMEDA (15.1 mmol) were added at 0 °C

to a solution of furan **13** (15.1 mmol) in 20 mL of THF, and the mixture was stirred at the same temperature for 3 h. The solution was cooled at -78 °C, and then δ -hexalactone **14** was added. The reaction mixture was stirred at -78 °C for 1 h and then quenched by adding 10 mL of a saturated aqueous solution of NH_4Cl . The mixture was extracted with Et_2O (3×20 mL) and CH_2Cl_2 (3×20 mL), and the organic layers were dried over Na_2SO_4 and filtered. The solvent was then evaporated at room temperature and the crude product was purified by flash chromatography (AcOEt/hexanes 2:1) to give compound **15** as a colorless oil in a 70% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, $J = 2.0$ Hz, 1H), 7.18 (d, $J = 3.6$ Hz, 1H), 6.52 (dd, $J = 3.6, 1.6$ Hz, 1H), 6.36 (bs, 1H, OH), 3.85–3.77 (m, 1H), 2.86 (t, $J = 7.2$ Hz, 2H), 1.87–1.75 (m, 2H), 1.54–1.48 (m, 2H), 1.20 (d, $J = 6.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 189.6, 152.5, 146.2, 117.0, 112.1, 67.3, 38.5, 38.0, 23.3, 20.1. Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{O}_3$: C 65.91, H 7.74. Found: C 65.01, H 7.20.

2-Hydroxy-8-methyl-1,7-dioxaspiro[5.5]undec-3-en-5-one (12a–d). NBS (0.2 mmol) was added to a solution of **15** (0.1 mmol) in 5 mL of THF/ H_2O (4:1) at 0 °C. The mixture was stirred for 1.5 h at 0 °C, quenched with 5 mL of an aqueous solution of $\text{Na}_2\text{S}_2\text{O}_3$, neutralized by adding an aqueous solution of NaHCO_3 , and extracted with CH_2Cl_2 (3×20 mL). The organic phase was separated, dried over Na_2SO_4 , filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography (AcOEt/hexanes 2:1) to give **12a–d** as a colorless oil in a 95% yield. ^1H NMR (400 MHz, CDCl_3) δ 6.95 (dd, $J = 14.0, 3.6$ Hz, 1Ha), 6.90 (dd, $J = 10.2, 1.2$ Hz, 1Hb), 6.12 (dd, $J = 10.2, 1.6$ Hz, 1Hb), 6.11 (dd, $J = 10.4, 0.8$ Hz, 1Ha), 5.67 (d, $J = 9.2$ Hz, 1Hb), 5.46 (dd, $J = 11.6, 2.8$ Hz, 1Ha), 4.38–4.30 (m, 1Ha), 4.04–3.96 (m, 1Hb), 2.18–2.06 (m, 1Ha, 1Hb), 1.96–1.84 (m, 1Ha, 1Hb), 1.77–1.48 (m, 3Ha, 3Hb), 1.39–1.31 (m, 1Ha, 1Hb), 1.16 (d, $J = 6.0$ Hz, 3Hb), 1.13 (d, $J = 6.4$ Hz, 3Ha). ^{13}C NMR (100 MHz, CDCl_3) 190.2, 178.2, 148.1, 145.2, 126.5, 124.7, 88.0, 87.3, 70.3, 69.1, 35.0, 34.0, 31.9, 27.7, 27.0, 21.4, 19.8, 17.9. Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{O}_4$: C 60.59, H 7.12. Found: C 60.90, H 7.27.

2. Chiral HPLC. Instrument. An Agilent Technologies (Waldbronn, Germany) 1100 series HPLC system [high-pressure binary gradient system equipped with a diode-array detector operating at multiple wavelengths (220, 254, 280, 360 nm), a 20 μL sample loop, and a thermostated column compartment] was employed for both analytical enantioseparations and multimilligram recovery of the enantiomers. Data acquisition and analysis were carried out with Agilent Technologies ChemStation version B.04.03 chromatographic data software. The UV absorbance is reported as milliabsorbance units (mAU).

Chromatography. Chiralcel OD-H (cellulose tris-3,5-dimethylphenylcarbamate) (Daicel, Japan) and Chiralpak IA (amylose tris-3,5-dimethylphenylcarbamate) (Chiral Technologies Europe, Ilkirch, France) were used as analytical chiral columns (250 mm $\times$ 4.6 mm, 5 μm). HPLC-grade *n*-hexane (hex) and 2-propanol (IPA) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Analyses were performed in isocratic mode. The retention factor (k) was determined as $k = (t_R - t_0)/t_0$, where t_R is the retention time for the eluted enantiomer; k_1 is the retention factor of the first-eluted enantiomer. The separation factor (α) was calculated as $\alpha = k_2/k_1$. The resolution (R_s) was determined as $2(t_{R2} - t_{R1})/(W_1 + W_2)$ where W is the base width of the peak. Dead time ($t_0 = 3.6$ min (OD-H), 3.8 min (IA)) was measured by injection of tri-*tert*-butylbenzene (Sigma-Aldrich, Germany) as a nonretained compound at flow rate FR = 0.8 mL/min.³⁹ For analytical runs, sample solutions were prepared by dissolving analytes in hex/IPA 1:1 (1.0–2.0 mg/mL). For multimilligram enantioseparations, the feed concentration of sample was 30 mg/mL (hex/IPA 1:1). Chromatographic separations were performed at 22 °C.

3. Cell Proliferation Inhibition Assay. Cell Lines. The study has been carried out using human tumor cell lines with different histological origin: MCF-7 breast carcinoma, M14 melanoma, H125 pulmonary carcinoma, HT-29 colon carcinoma, HL-60 promyelocytic leukemia. SH-SY5Y subline of the neuroblastoma cell line SK-N-SH, MCF7, H125, HT29 SH-SY5Y, and HL60 were obtained from

American Type Culture Collection (Rockville, MD). M14 (Golub et al., 1992) was kindly provided by Dr. G. Zupi (Istituto Regina Elena, Rome, Italy). All cell lines were cultured at 37 °C in 5% CO₂ humidified atmosphere and maintained in RPMI-1640 or DMEM F12 (Hyclone Europe, Cramlington, U.K.) supplemented with 10% heat-inactivated (56 °C, 30 min) fetal calf serum (Hyclone Laboratories, Logan, UT), 2 mM L-glutamine, and antibiotics (Life Technologies Ltd., Paisley, Scotland) (referred to as complete medium, CM). Adherent cells were released from flasks by brief exposure to 0.025% trypsin with 0.01% EDTA.

Antiproliferative Activity. Cell growth and viability were determined by trypan blue dye exclusion test. Cells were seeded in 24-well tissue culture plates (Falcon) at a concentration of 5×10^4 cells/mL and allowed to adhere overnight. Cells were incubated with **12a–d** (7.8–250 nM) or DMSO alone as control, 3 wells for each treatment. The plates were incubated at 37 °C in a 5% CO₂ humidified atmosphere for 24, 48, or 72 h. Cell growth and viability were evaluated every 24 h. Trypsinized cells were manually counted using a hemocytometer, and cell viability was determined by trypan blue dye exclusion assay.

The effect of **12a–d** or enantiomer **12a** and **12b** on cell proliferation of melanoma cell line M14 was determined by the CellTiter 96 nonradioactive cell proliferation assay (Promega Madison, WI, USA). Briefly, the cell suspension at an initial density of 8×10^4 cells/mL was seeded into 96-well plates and allowed to adhere overnight. Then, cells were treated with DMSO alone as control and **12a–d**, **12a**, and **12b** (62.5, 125, 250 nM) for 6, 12, 24, 48, and 72 h. After treatment, the dye solution was added to the cell culture. Following incubation for 4 h, the solubilization/stop solution was added to each well. The absorbance at wavelength of 570 nm was measured by an enzyme-linked immunoabsorbent assay reader. The negative control well contained medium only and was used as zero point of absorbance. The relative inhibition rate was calculated as a percentage as follows: $[(A_{\text{control}} - A_{\text{experiment}})/(A_{\text{control}} - A_{\text{negative control}})] \times 100$.

4. Caspase-Glo 3/7 Assay. To confirm apoptosis induction, caspase-3/7 activities were measured using Caspase-Glo 3/7 assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.⁴⁰ Briefly, tumor cells SHSY5Y were seeded in 96-well tissue culture plates (Falcon) at a concentration of 5×10^4 cells/mL and allowed to adhere overnight. After that the cells were exposed to **12a–d** (7.8–31.2 nM) for 24 h. The cells were incubated for 1 h at 37 °C with equal volume of Caspase-Glo 3/7 reagent to the volume of culture medium. Adding the Caspase-Glo 3/7 reagent in an “add–mix–measure” format results in cell lysis, followed by caspase cleavage of the substrate. This liberates free aminoluciferin, which is consumed by the luciferase, generating a “glow-type” luminescent signal. The luminescence that is proportional to caspase 3/7 activities was determined by luminometer. A negative control consisting of cells treated with DMSO supernatant containing **12a–d** alone was also included in each assay. The test was performed in triplicate.

5. Telomerase in Vitro Activity. In order to evaluate telomerase activity, MCF-7, H-125, M14, and H125 tumor cells were treated for 48 h with serial doses of **12a–d** (from 31.2 to 250 nM) as described above. At the end of the treatment, the cells were harvested and washed twice with washing buffer and lysed in the lysis buffer. Supernatants were collected, rapidly frozen, and stored at –80 °C until the use. The telomerase activity was determined using the TeloTAGGG telomerase PCR-ELISA plus detection kit according to the manufacturer's protocol (Roche Applied Science, Germany). Briefly, the cell extracts were incubated in the presence of biotin-labeled primers for 30 min and the telomeric repeats were built by cell-extracted telomerase. Subsequently, the elongated products and the especial internal standard were amplified by PCR, and then the PCR products were denatured and split into two aliquots, each was separately hybridized to a digoxigenin-labeled detection specific probe and was then allowed to bind to a streptavidin coated 96-well plate, and the biotin-labeled PCR products were detected using peroxidase-conjugated antibody. Finally, the absorbance of developed blue color was measured at 450 nm by an ELISA reader. The telomerase activity

was measured in triplicate. As the negative control, each extract was heated at 95 °C for 10 min prior to the PCR step. Relative telomerase activity (RTA) of each sample was calculated according to the instruction of TeloTAGGG telomerase PCR-ELISA PLUS kit.

6. Circular Dichroism Studies. *Preparation of the ODN Model System.* The human telomeric sequence 5'-d(AGGGTTA-GGGTTAGGGTTAGGG)-3' (Tel-22) was obtained from Eurofins Genomics (Ebersberg, Germany). DNA samples were prepared by dissolving the deoxyoligonucleotide in 0.01 M Tris-HCl (pH 7.5), 0.2 M KCl, and PBS 1× (pH 7.5), followed by an annealing process in which the DNA solution was heated to 95 °C and slowly cooled to 4 °C over 12 h. The formation of the G4 was confirmed at a concentration of 2.5 μM (strand) in a 1 cm path length cell using a Jasco J-810 spectropolarimeter: CD spectra in TRIS-K⁺ buffer showed a positive CD band centered at about 295 nm, which is characteristic of antiparallel G4 DNA structure, while in PBS 1× Tel-22 gave a CD spectrum compatible with that previously reported in the literature (Hudson et al., 2014).

CD-Monitored Melting Experiments. For the CD melting experiments, the ellipticity has been recorded at 295 nm with a temperature scan rate of 1 °C/min in the range 10–90 °C. T_m values of 60 and 69 °C have been determined, respectively, for the G4 model systems in our two buffer conditions (0.01 M Tris-HCl (pH 7.5), 0.2 M KCl, and PBS 1× (pH 7.5)). All the CD melting experiments have been performed in triplicate in a 1 cm path length cell at 2.5 μM concentration of G4.

7. Docking Studies. 3D structures of **12a** and **12b** were generated using LigPrep, version 3.8 (Schrödinger, LLC, New York, NY, 2016,) and *Tribolium castaneum* catalytic subunit of telomerase tTERT in complex with highly specific BIBR1532 inhibitor (PDB code 5CQG) was prepared with Protein Preparation Wizard. Grid receptor generation and docking studies were performed using Glide, while the receptor was kept rigid (version 7.1, Schrödinger, LLC, New York, NY, 2016).

Statistical Analysis. Results are mean values ± SE. Statistical significance was determined using Student's *t* test.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.6b01046.

Molecular formula strings and some data (CSV)

■ AUTHOR INFORMATION

Corresponding Authors

*M.P.F.: e-mail, mariapia.fuggetta@ift.cnr.it; phone, +39 06 49934610.

*P.S.: e-mail, p.spanu@icb.cnr.it; phone, +39 079 2841221.

Author Contributions

The manuscript was written through contributions of all authors.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This study was supported by Fase1 srl Viale Trento, 69 Cagliari, Italy.

■ ABBREVIATIONS USED

TELMA, telomeric activity; OD, optical density; G4, G-quadruplex; CD, circular dichroism; IPA, 2-propanol; ODN, oligonucleotide

■ REFERENCES

- (1) Perron, F.; Albizati, K. F. Chemistry of Spiroketal. *Chem. Rev.* **1989**, *89*, 1617–1661.
- (2) Aho, J. E.; Pihko, P. M.; Rissa, T. K. Nonanomeric Spiroketal in Natural Products: Structures, Sources, and Synthetic Strategies. *Chem. Rev.* **2005**, *105*, 4406–4440 and references cited therein.
- (3) Pettit, G. R.; Chicacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. Antineoplastic Agents. 257. Isolation and Structure of Spongistatin 1. *J. Org. Chem.* **1993**, *58*, 1302–1304.
- (4) Singh, S. B.; Zink, D. L.; Heimbach, B.; Genilloud, O.; Teran, A.; Silverman, K. C.; Lingham, R. B.; Felock, P.; Hazuda, D. J. Structure, Stereochemistry, and Biological Activity of Integramycin, a Novel Hexacyclic Natural Product Produced by *Actinoplanes* sp. that Inhibits HIV-1 Integrase. *Org. Lett.* **2002**, *4*, 1123–1126.
- (5) Takahashi, H.; Osada, H.; Koshino, H.; Kudo, T.; Amano, S.; Shimizu, S.; Yoshihama, M.; Isono, K. Reveromycins, new inhibitors of eukaryotic cell growth. I. Producing organism, fermentation, isolation and physico-chemical properties. *J. Antibiot.* **1992**, *45*, 1409–1413.
- (6) Takahashi, H.; Osada, H.; Koshino, H.; Sasaki, M.; Onose, R.; Nakakoshi, M.; Yoshihama, M.; Isono, K. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. *J. Antibiot.* **1992**, *45*, 1414–1419.
- (7) Takahashi, H.; Yamashita, Y.; Takaoka, H.; Nakamura, J.; Yoshihama, M.; Osada, H. Inhibitory Action of Reveromycin A on TGF- α -dependent Growth of Ovarian Carcinoma BG-1 in vitro and in vivo. *Oncol. Res.* **1997**, *9*, 7–11.
- (8) Cohen, P. The structure and regulation of protein phosphatases. *Annu. Rev. Biochem.* **1989**, *58*, 453–508.
- (9) Tachibana, K.; Scheuer, P. J.; Tsukitani, Y.; Kikuchi, H.; Van Engen, D.; Clardy, J.; Gopichand, Y.; Schmitz, F. J. Okadaic Acid, a Cytotoxic Polyether from Two Marine Sponges of the Genus *Halichondria*. *J. Am. Chem. Soc.* **1981**, *103*, 2469–2471.
- (10) Takai, A.; Murata, M.; Torigoe, K.; Isobe, M.; Mieskes, G.; Yasumoto, T. Inhibitory Effect of Okadaic Acid Derivatives on Protein Phosphatases. *Biochem. J.* **1992**, *284*, 539–544.
- (11) Marjanovic, J.; Kozmin, S. A. Spirofungin A: Stereoselective Synthesis and Inhibition of Isoleucyl-tRNA Synthetase. *Angew. Chem., Int. Ed.* **2007**, *46*, 8854–8857.
- (12) Ueno, T.; Takahashi, H.; Oda, M.; Mizunuma, M.; Yokoyama, A.; Goto, Y.; Mizushima, Y.; Sakaguchi, K.; Hayashi, H. Inhibition of Human Telomerase by Rubromycins: Implication of Spiroketal System of the Compounds as an Active Moiety. *Biochemistry* **2000**, *39*, 5995–6002.
- (13) Chen, J. L.-Y.; Sperry, J.; Ip, N. Y.; Brimble, M. A. Natural Products Targeting Telomere Maintenance. *MedChemComm* **2011**, *2*, 229–245.
- (14) Atkinson, D. J.; Brimble, M. A. Isolation, Biological Activity, Biosynthesis and Synthetic Studies towards the Rubromycin Family of Natural Products. *Nat. Prod. Rep.* **2015**, *32*, 811–840.
- (15) Mocellin, S.; Pooley, K. A.; Nitti, D. Telomerase and the Search for the End of Cancer. *Trends Mol. Med.* **2013**, *19*, 125–133.
- (16) Kiran, K. G.; Palaniswamy, M.; Angayarkanni, J. Human Telomerase Inhibitors from Microbial Source. *World J. Microbiol. Biotechnol.* **2015**, *31*, 1329–1341.
- (17) Rizvi, S. A.; Liu, S.; Chen, Z.; Skau, C.; Pytynia, M.; Kovar, D. R.; Chmura, S. J.; Kozmin, S. A. Rationally Simplified Bistramide Analog Reversibly Targets Actin Polymerization and Inhibits Cancer Progression in Vitro and in Vivo. *J. Am. Chem. Soc.* **2010**, *132*, 7288–7290.
- (18) Kamachi, H.; Tanaka, K.; Yanagita, R. C.; Murakami, A.; Murakami, K.; Tokuda, H.; Suzuki, N.; Nakagawa, Y.; Irie, K. Structure–Activity Studies on the Side Chain of a Simplified Analog of Aplysiatoxin (aplog-1) with anti-Proliferative Activity. *Bioorg. Med. Chem.* **2013**, *21*, 2695–2702.
- (19) Smith, A. B.; Risatti, C. A.; Atasoylu, O.; Bennett, C. S.; Tendyke, K.; Xu, Q. Design, Synthesis, and Biological Evaluation of EF- and ABEF- Analogues of (+)-Spongistatin 1. *Org. Lett.* **2010**, *12*, 1792–1795.
- (20) Uckun, F. M.; Mao, C.; Vassilev, A. O.; Huang, H.; Jan, S. T. Structure-Based Design of a Novel Synthetic Spiroketal Pyran as a Pharmacophore for the Marine Natural Product Spongistatin 1. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 541–545.
- (21) Barun, O.; Kumar, K.; Sommer, S.; Langerak, A.; Mayer, T. U.; Müller, O.; Waldmann, H. Natural Product-Guided Synthesis of a Spiroacetal Collection Reveals Modulators of Tubulin Cytoskeleton Integrity. *Eur. J. Org. Chem.* **2005**, *2005*, 4773–4788.
- (22) Mitsunashi, S.; Shima, H.; Kawamura, T.; Kikuchi, K.; Oikawa, M.; Ichihara, A.; Oikawa, H. The Spiroketal Containing a Benzyloxymethyl Moiety at C8 Position Showed the Most Potent Apoptosis-Inducing Activity. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2007–2012.
- (23) Krohn, K.; Sohrab, Md. H.; Van Ree, T.; Draeger, S.; Schulz, B.; Antus, S.; Kurtán, T. Dinemasones A, B and C - New Bioactive Metabolites from the Endophytic Fungus *Dinemasporium strigosum*. *Eur. J. Org. Chem.* **2008**, *2008*, 5638–5646.
- (24) De Mico, A.; Cottarelli, A.; Fuggetta, M.; Lanzilli, G.; Tricarico, M. Dioxaspiroketal Derivatives, Process for Their Preparation and Uses Thereof. WO2007/132496, 2007; US20100227919, 2010.
- (25) Perron, F.; Albizati, K. F. Synthesis of Oxidized Spiroketal via 2-Furyl Ketone Oxidation-Rearrangement. *J. Org. Chem.* **1989**, *54*, 2044–2047.
- (26) De Haan, R. A.; Heeg, M. J.; Albizati, K. F. Synthesis of the Trioxa-Tricyclic Subunit of Saponaceolides via 2-Furyl Ketone Oxidation-Rearrangement. *J. Org. Chem.* **1993**, *58*, 291–293.
- (27) Aho, J. E.; Pihko, P. M.; Rissa, T. K. Nonanomeric Spiroketal in Natural Products: Structures, Sources, and Synthetic Strategies. *Chem. Rev.* **2005**, *105*, 4406–4440.
- (28) Fuggetta, M. P.; Lanzilli, G.; Tricarico, M.; Cottarelli, A.; Falchetti, R.; Ravagnan, G.; Bonmassar, E. Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. *J. Exp. Clin. Cancer Res.* **2006**, *25*, 189–193.
- (29) Lanzilli, G.; Fuggetta, M. P.; Tricarico, M.; Cottarelli, A.; Serafino, A.; Falchetti, R.; Ravagnan, G.; Turriziani, M.; Adamo, R.; Franzese, O.; Bonmassar, E. Resveratrol Down-Regulates the Growth and Telomerase Activity of Breast Cancer Cells in Vitro. *Int. J. Oncol.* **2006**, *28*, 641–648.
- (30) Chen, C.-L.; Chang, D.-M.; Chen, T.-C.; Lee, C.-C.; Hsieh, H.-H.; Huang, F.-C.; Huang, K.-F.; Guh, J.-H.; Lin, J.-J.; Huang, H.-S. Structure-Based Design, Synthesis and Evaluation of Novel anthra[1,2-D]imidazole-6,11-Dione Derivatives as Telomerase Inhibitors and Potential for Cancer Polypharmacology. *Eur. J. Med. Chem.* **2013**, *60*, 29–41.
- (31) Shirgahi Talari, F.; Bagherzadeh, K.; Golestanian, S.; Jarstfer, M.; Amanlou, M. Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays. *J. Chem. Inf. Model.* **2015**, *55*, 2596–2610.
- (32) Ruden, M.; Puri, N. Novel Anticancer Therapeutics Targeting Telomerase. *Cancer Treat. Rev.* **2013**, *39*, 444–456.
- (33) Moye, A. L.; Porter, K. C.; Cohen, S. B.; Phan, T.; Zyner, K. G.; Sasaki, N.; Lovrecz, G. O.; Beck, J. L.; Bryan, T. M. Telomeric G-Quadruplexes Are a Substrate and Site of Localization for Human Telomerase. *Nat. Commun.* **2015**, *6*, 7643.
- (34) Ruden, M.; Puri, N. Novel Anticancer Therapeutics Targeting Telomerase. *Cancer Treat. Rev.* **2013**, *39*, 444–456.
- (35) Hudson, J. S.; Ding, L.; Le, V.; Lewis, E.; Graves, D. Recognition and binding of human telomeric G-quadruplex DNA by unfolding protein 1. *Biochemistry* **2014**, *53*, 3347–3356.
- (36) Steczkiewicz, K.; Zimmermann, M. T.; Kurcinski, M.; Lewis, B. A.; Dobbs, D.; Kloczkowski, A.; Jernigan, R. L.; Kolinski, A.; Ginalski, K. Human Telomerase Model Shows the Role of the TEN Domain in Advancing the Double Helix for the next Polymerization Step. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 9443–9448.
- (37) Bryan, C.; Rice, C.; Hoffman, H.; Harkisheimer, M.; Sweeney, M.; Skordalakes, E. Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532. *Structure* **2015**, *23*, 1934–1942.

- (38) Kuhn, B.; Fuchs, J. E.; Reutlinger, M.; Stahl, M.; Taylor, N. R. Rationalizing Tight Ligand Binding through Cooperative Interaction Networks. *J. Chem. Inf. Model.* **2011**, *51*, 3180–3198.
- (39) Koller, H.; Rimböck, K.-E.; Mannschreck, A. High-Pressure Liquid Chromatography on Triacetylcellulose – Characterization of Sorbent for the Separation of Enantiomers. *J. Chromatogr. A* **1983**, *282*, 89–94.
- (40) Chakravarti, B.; Maurya, R.; Siddiqui, J. A.; Bid, H. K.; Rajendran, S. M.; Yadav, P. P.; Konwar, R. In vitro anti-breast cancer activity of ethanolic extract of *Wrightia tormentosa*: role of pro-apoptotic effects of oleanolic acid and ursolic acid. *J. Ethnopharmacol.* **2012**, *142*, 72–79.